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Abstract
The International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes convened a consensus working
groupofdiabetologists,endocrinologists,surgeonsandpublichealthexpertstoreviewtheappropriateroleofsurgeryandother
gastrointestinal interventions in the treatment and prevention of Type 2 diabetes. The speciﬁc goals were: to develop practical
recommendations for clinicians on patient selection; to identify barriers to surgical access and suggest interventions for health
policychangesthatensureequitableaccesstosurgerywhenindicated;andtoidentifyprioritiesforresearch.Bariatricsurgerycan
signiﬁcantly improve glycaemic control in severely obese patients with Type 2 diabetes. It is an effective, safe and cost-effective
therapy for obese Type 2 diabetes. Surgery can be considered an appropriate treatment for people with Type 2 diabetes and
obesity not achieving recommended treatment targets with medical therapies, especially in the presence of other major
co-morbidities. The procedures must be performed within accepted guidelines and require appropriate multidisciplinary
assessment for the procedure, comprehensive patient education and ongoing care, as well as safe and standardized surgical
procedures. National guidelines for bariatric surgery need to be developed for people with Type 2 diabetes and a BMI of
35 kg⁄m
2 or more.
Diabet. Med. 28, 628–642 (2011)
Review criteria
The working group reviewed literature focusing on bariatric
surgery published between 1991 and 2010, in the areas of
national and international guidelines, systematic reviews of the
literature and high-quality clinical trials for the treatment of
obesity and diabetes in adults and adolescents. The group
synthesized the available evidence for efﬁcacy, safety and cost-
effectivenessoftheestablishedbariatricproceduresinrelationto
current standard therapy for people with obesity and Type 2
diabetes. The group also explored weight loss and non-weight
loss effects of the surgery on glycaemic control and novel
gastrointestinal procedures and devices being developed to treat
Type 2 diabetes. All papers identiﬁed were English-language,
full-text papers.
Executive Summary
Text Box 1: Background
• Obesity and Type 2 diabetes are serious chronic diseases
associated with complex metabolic dysfunctions that increase
the risk for morbidity and mortality.
• The dramatic rise in the prevalence of obesity and diabetes has
become a major global public health issue and demands urgent
attention from governments, healthcare systems and the
medical community.
• Continuing population-based efforts are essential to prevent
the onset of obesity and Type 2 diabetes. At the same time,
effective treatment must also be available for people who have
developed Type 2 diabetes.
• Faced with the escalating global diabetes crisis, healthcare
providers require as potent an armamentarium of therapeutic
interventions as possible.
• In addition to behavioural and medical approaches, various
types of surgery on the gastrointestinal tract, originally
developed to treat morbid obesity (‘bariatric surgery’), consti-
tute powerful options to ameliorate diabetes in severely obese
patients, often normalizing blood glucose levels, reducing or
avoiding the need for medications and providing a potentially
cost-effective approach to treating the disease.
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• Bariatric surgery is an appropriate treatment for people with
Type 2 diabetes and obesity not achieving recommended
treatment targets with medical therapies, especially when there
are other major co-morbidities.
• Surgery should be an accepted option in people who have
Type 2 diabetes and a BMI of 35 kg⁄m
2 or more.
• Surgery should be considered as an alternative treatment
option in patients with a BMI between 30 and 35 kg⁄m
2
when diabetes cannot be adequately controlled by optimal
medical regimen, especially in the presence of other major
cardiovascular disease risk factors.
• In Asian, and some other ethnicities of increased risk, BMI
action points may be reduced by 2.5 kg⁄m
2.
• Clinically severe obesity is a complex and chronic medical
condition. Societal prejudices about severe obesity, which also
exist within the healthcare system, should not act as a barrier
to the provision of clinically effective and cost-effective
treatment options.
• Strategies to prioritize access to surgery may be required to
ensure that the procedures are available to those most likely to
beneﬁt.
• Available evidence indicates that bariatric surgery for obese
patients with Type 2 diabetes is cost-effective.
• Bariatric surgery for Type 2 diabetes must be performed within
accepted international and national guidelines. This requires
appropriate assessment for the procedure and comprehensive
and ongoing multidisciplinary care, patient education, follow-
up and clinical audit, as well as safe and effective surgical
procedures. National guidelines for bariatric surgery in people
with Type 2 diabetes and a BMI of 35 kg⁄m
2 or more need to
be developed and promulgated.
• The morbidity and mortality associated with bariatric surgery
is generally low and similar to that of well-accepted procedures
such as elective gall bladder or gallstone surgery.
• Bariatric surgery in severely obese patients with Type 2
diabetes has a range of health beneﬁts, including a reduction
in all-cause mortality.
• A national registry of persons who have undergone bariatric
surgery should be established in order to ensure quality patient
care and to monitor both short- and long-term outcomes.
• In order to optimize the future use of bariatric surgery as a
therapeutic modality for Type 2 diabetes, further research is
required.
Introduction
Why is this position statement needed?
The global prevalence of Type 2 diabetes is rising dramatically,
driven by an ‘obesogenic’ environment that favours increasing
sedentary behaviour and easier access to attractive calorie-dense
foodsactingonsusceptiblegenotypes[1].Themostrecentglobal
predictions by the International Diabetes Federation (IDF)
suggest that there are 285 million people with diabetes
currently worldwide. This is set to escalate to 438 million by
2030 [2], with a further half billion at high risk. Diabetes is
looming as one of the greatest public health threats of the 21st
century.
Type 2 diabetes is a risk factor for vascular damage: both
microvascular (retinopathy; nephropathy and neuropathy) and
macrovascular (premature and more extensive cardio-, cerebro-
and peripheral vascular disease). Premature mortality and
morbidity in diabetes result from such complications. The
disease results from inadequate insulin production and action
and results in hyperglycaemia, but is also associated with
multiple other dysfunctions involving lipid metabolism,
oxidative stress, inﬂammation and haemato-rheology. In
addition, obesity, by itself, generates similar cardio-metabolic
dysfunction [3].
Thedramaticriseinthe prevalenceofobesityanddiabeteshas
become a major global public health issue [2]. The problem is
complex [4] and will require strategies at many levels to prevent,
control and manage.
There is increasing evidence that the health of obese people
withType 2diabetes,includingthemetaboliccontrolofdiabetes
and its associated risk factors, can beneﬁt substantially from
bariatric surgery—that is, surgical procedures to produce
substantial weight loss [5,6].
Several gastrointestinal (GI) operations that were originally
designed to treat morbid obesity also cause dramatic
improvement of Type 2 diabetes and can effectively prevent
progression from impaired glucose tolerance to diabetes in
severely obese individuals [7]. In addition, bariatric surgery has
been shown to substantially improve hypertension, dyslipida-
emia and sleep apnoea [8] and several reports have documented
an improvement of overall survival [5] and speciﬁc reduction in
diabetes-related mortality [9].
Despite a number of evidence-based reviews and consensus
statements having been published regarding the utilization of
bariatric surgery in patients with obesity and diabetes [10–15],
the IDF has not previously considered this rapidly developing
area of care for worldwide use. Therefore, a need exists for
worldwide expert guidance in the preoperative evaluation,
choice of interventional procedure, perioperative management
and long-term care of patients who seek surgery to improve
diabetes control.
The IDF Taskforce on Epidemiology and Prevention con-
vened a consensus working group of diabetologists, endo-
crinologists, surgeons and public health experts in December
2010 to discuss the appropriate role of bariatric surgery and
other gastrointestinal interventions in the treatment and
prevention of obesity and Type 2 diabetes. The speciﬁc goals of
the panel were: to develop practical recommendations for
clinicians; to identify barriers that currently prevent access to
surgery and suggest interventions for health policy changes
that ensure equitable access to surgery when indicated; and to
identify priorities for clinical research.
This consensus statement considers primarily established
bariatric surgical procedures. It is acknowledged that this is an
emerging ﬁeld and there is a large range of novel extraluminal
andendoluminalgastrointestinalsurgicalproceduresanddevices
that are in the development phase. Some focus primarily on
weight loss and others additional non-weight loss metabolic
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can be recommended.
How is obesity deﬁned?
Obesity is usually classiﬁed by body mass index (BMI),
calculated as body weight in kilograms divided by the height
in metres squared (kg⁄m
2). Classiﬁcations of BMI, as deﬁned
by the World Health Organization (WHO), based on
associations with adverse health consequences, are listed in
Table 1. Other methods, including waist circumference and
central and peripheral fat mass, have also been used, but
currently the clearest evidence suggests continued use of BMI
as an index of obesity, particularly when BMI exceeds
30 kg⁄m
2.
BMI categories have been developed primarily in
populations of mainly European ethnicity, and often
underestimate health risks in other populations. In addition,
BMI does not necessarily reﬂect the proportion of body weight
that consists of fat or the distribution of fat: both these aspects
of body composition can affect the health risks of excess
weight. Nevertheless, at present, in the absence of a better
alternative, BMI is the internationally accepted standard used
by researchers and policymakers to allocate individuals to
different size categories.
Clinically severe or ‘morbid’ obesity is considered to be
class IIIobesityorclass IIobesitywithsigniﬁcantobesity-related
co-morbidity, including Type 2 diabetes (Table 1). Additional
cut-pointsforpublichealthactionhavebeensuggestedtoaddress
theincreasedriskofdiabetesandcardiovasculardiseaseinAsian
populations and further investigation should examine other
at-risk ethnicities.
The link between obesity and Type 2 diabetes
Type 2 diabetesis a heterogeneousdisorderand, while itscauses
have yet to be fully explained, obesity is considered the primary
risk factor [16]. It has been estimated that the risk of developing
Type 2 diabetes is increased 93-fold in women and 42-fold in
men who are severely obese rather than of healthy weight
[17,18]. A small proportion of people with Type 2 diabetes,
approximately 15% in populations of European origin, are not
overweight [19].
In the short term, even modest weight loss in people with
Type 2 diabetes who are overweight or obese is associated with
improvements in glycaemic control and associated conditions
such as hypertension and dyslipidaemia [20]. However, there is
strong evidence that signiﬁcant weight loss achieved by using
lifestyle and medical methods by obese, particularly severely
obese, people is modest and rarely sustained, particularly in the
severely obese [5,21,22]. There are now few medications
approved for weight loss with recent withdrawals associated
with adverse events.
Negative attitudes toward obesity
There are widely held community attitudes that the majority
of obese individuals are responsible for their current weight.
Severe obesity is too often misconstrued as a ‘cosmetic’ problem
and a result of personal failure or lack of motivation.
However, this perspective ignores the very strong genetic
and developmental bases to severe obesity [23] compounded by
physical, emotional and societal issues. It also fails to consider
the pervasive obesity-promoting effects of modern societies
(the ‘obesogenic environment’) [24], where an abundant food
supply, changes in food preparation, increasing sedentary
behaviour and other lifestyle factors mitigate against weight
control for individuals. Additionally, it ignores the emerging
evidencethatbodyweightisdefended bypowerfulphysiological
mechanisms [25,26], making long-term maintenance of weight
loss difﬁcult.
In the context of treatment, negative societal attitudes have
been a barrier to the provision of clinically effective, and cost-
effective, health care for people with severe obesity and Type 2
diabetes [27,28]. As noted earlier, obesity is a complex,
multifactorial and chronic disorder with serious adverse
consequences for health, which requires a comprehensive
approach to both prevention and treatment. People affected by
severeobesityoftenstrugglenotonlywiththehealthandphysical
consequences of their chronic condition, but discrimination at
work, socially and within the healthcare system.
Why consider bariatric surgery?
Both insulin resistance and insulin secretory reserve are
important in the pathogenesis of Type 2 diabetes [29], but to
different extents in different people. It is very important to
recognize that not all Type 2 diabetes is the same and it is
Table 1 The classiﬁcation of weight category by BMI
Classiﬁcation
BMI (kg⁄m
2)
Principal cut-off
points
Cut-off points
for Asians*
Normal range 18.5–24.9 18.5–22.9
23.0–24.9
Pre-obese 25.0–29.9 25.0–27.4
27.5–29.9
Obese class I 30.0–34.9 30.0–32.4
32.5–34.9
Obese class II 35.0–39.9 35.0–37.4
37.5–39.9
Obese class III ‡ 40.0 ‡ 40.0
*For Asian populations, classiﬁcations remain the same as the
international classiﬁcation, but that public health action points
for interventions are set at 23, 27.5, 32.5 and 37.5 kg⁄m
2 [74].
We address eligibility and prioritization for bariatric surgery
within the coloured zones above.
Source: Adapted from the World Health Organization (WHO)
2004 [75].
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different phenotypes often resulting to suboptimal responses to
therapy.
Type 2 diabetes is a progressive disease and the usual natural
history is of progressive loss of insulin secretory capacity over
time and the need for intensiﬁcation of therapy and
polypharmacy [30]. Arresting this progression is a formidable
therapeutic challenge. Treatment for Type 2 diabetes must also
include active management of all cardiovascular risk factors
(hypertension, dyslipidaemia, smoking and inactivity) but
glycaemic control is very important—and not just for
prevention of microvascular disease. Years of improved
glycaemic control continue to deliver reduced risk of
macrovascular disease and mortality over subsequent years
[31,32].
Given the role of obesity in the aetiology of Type 2 diabetes,
guidelinesonitstreatmentprovidethatweightloss,withitsmany
beneﬁts, should be the most logical and cost-effective means of
controlling Type 2 diabetes [16]. Lifestyle interventions to
promote weight loss and increase physical activity should be
included as an essential component of diabetes treatment
regimens.
Medical therapeutic options targeting primarily glucose
control are all ideally added to, and not exchanged for, lifestyle
change. Unfortunately, such strategies have very limited success
in controlling blood glucose levels amongst the severely obese,
with many of these patients not achieving targets. A number of
these medications used for treating Type 2 diabetes, including
insulin, themselves can result in weight gain.
A major problem for managing Type 2 diabetes is the need
for continuous monitoring and intensiﬁcation of therapies by
adding new agents in increasing doses over time. The American
Diabetes Association (ADA) and European Association for the
Study of Diabetes (EASD) consensus statement recommends
that an HbA1c of 7% (53 mmol⁄mol) is a call to action [33].
Some national guidelines, such as those from the UK’s National
Institute for Health and Clinical Excellence (NICE) [12],
support more vigorous intensiﬁcation of glycaemic therapies
in the early stages of diabetes. NICE used HbA1c ‡ 6.5%
(48 mmol⁄mol) to increase from monotherapy, but ‡ 7%
(53 mmol⁄mol) for increasing to triple therapies and beyond.
This is very important. In one trial that randomized people
with Type 2 diabetes and existing cardiovascular disease
to very intensive management targeting HbA1c <6 . 5 %
(48 mmol⁄mol), mortality was higher in the intensive group,
driven by deaths in those people who failed to show HbA1c
improvement as treatment was intensiﬁed [31]. This should not
be taken to mean people with early Type 2 diabetes should be
treated less vigorously as the legacy effect of early intervention is
considerable [34].
A critical issue has been the rate at which healthcare
professionals escalate therapies. Current approaches that rely
on loss of glycaemic control andon intensifying lifestyle or other
time-consuming measures set clinicians up for failure to achieve
targets [35].
It may be possible to achieve much more in terms of
complication prevention—or even possibly slowed rate of
progression—if treatments are started and intensiﬁed early.
There have even been suggestions of starting polypharmacy at
diagnosis [36,37], but there is limited current evidence to
demonstrate the efﬁcacy of this [31].
Apartfromtheside-effectproﬁlesandsuboptimaldeployment
ofexistingmedicaldiabetestherapies,thereremainissuesaround
patient engagement in many aspects of their lives. Very few
clinical services routinely provide psychological support to
encourage lifelong engagement in self-care.
The continuing morbidity and mortality in persons with
diabetes is a sign that the answer as to the best management for
Type 2 diabetes in terms of maximizingmetabolic control is still
elusive. Given this scenario, the option of bariatric intervention
needs to be considered in appropriately selected individuals.
Evolving concept: bariatric–metabolic surgery
The term ‘bariatric’ surgery, derived from the Greek word baros
for weight, deﬁnes surgical procedures designed to produce
substantial weight loss. Accordingly, goals of bariatric surgery
originallyevolvedaroundachievingsubstantialsustainedweight
loss. In reality, weight loss is only one of the outcomes of
suchsurgery.Bariatricsurgerycanbeassociatedwithsubstantial
other health beneﬁts, including improvement or normalization
of hyperglycaemia. hyperlipidaemia, blood pressure, obstructive
sleep apnoea and improved quality of life [38].
In view of the broad beneﬁts of weight loss and the growing
evidence that some bariatric procedures provide metabolic
changes that cannot be explained completely by their effects on
bodyweightalone[39],thename‘bariatric–metabolicsurgery’is
emerging as a more appropriate name.
Bariatric surgery and Type 2 diabetes
Bariatric procedures aim to reduce weight and maintain weight
loss through altering energy balance, primarily by reducing food
intake and modifying the physiological changes that drive
weight regain. There also appear to be independent metabolic
beneﬁts, associated with effects of incretins and possibly other
hormonal or neural changes after some surgical procedures
[40], in addition to weight loss. For example, rapid and
sustained improvements in glycaemic control can be achieved
within days of gastric bypass surgery, before any signiﬁcant
weight loss is evident [41,42].
A 2009 Cochrane review including patients with and without
diabetes concluded that bariatric surgery resulted in greater
weight loss than conventional treatment in obese class I (BMI
>3 0k g⁄m
2) as well as severe obesity, accompanied by
improvements in co-morbidities such as Type 2 diabetes,
hypertension and improvements in health-related quality of
life [38].
A less rigorous systematic review and meta-analysis of 621
studies which included approximately 135 000 patients
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and⁄or laboratory manifestations of diabetes [6]. Overall,
78.1% of patients had ‘remission’ of diabetes following
surgery. Among patients with diabetes at baseline, 62%
remained in remission more than 2 years after surgery. There
were signiﬁcant limitations to this review as remission was
largely based on clinical reporting, not HbA1c or other
biochemical outcomes, and follow-up of most cohorts poorly
described.
The Swedish Obese Subjects study clearly demonstrated the
preventionandsustainedremissionofType 2diabetesinagroup
of 2037 [7] severely obese patients electing to have bariatric
surgery when compared with well-matched controls at 2 and
10 years follow-up (Table 2).
The extent of remission of Type 2 diabetes is inﬂuenced by
the extent of weight loss, weight regain, duration of diabetes,
the pre-surgery hypoglycaemic therapy requirements, and the
choice of bariatric procedure. In addition, each patient’s
commitment to modifying their diet and levels of exercise
within a framework of ongoing multidisciplinary care will
inﬂuence outcomes.
Remarkably, there is only a sole acceptably designed
prospective randomized control trial (RCT) which has
investigated bariatric surgery speciﬁcally as a treatment for
Type 2 diabetes [43]. It compared laparoscopic adjustable
gastric banding as part of a comprehensive management
programme to conventional diabetes therapy with a focus on
weight loss by diet and exercise. After 2 years, remission of
diabetes was signiﬁcantly more common in those who had
received surgery (73 vs. 13%).
Bariatric surgery beneﬁts beyond diabetes?
Severe obesity is associated with a large number of health
problems in addition to Type 2 diabetes. A review of more
than 1.4 million participants in prospective studies largely from
North America, Europe and Australia show a consistent
progressive rise in the mortality hazard ratios with increasing
BMI[44] (Table 3). Asimilaranalysisby the Prospective Studies
Collaboration found the risk of diabetes-related death was
quadrupled for morbidly obese individuals [45].
Follow-upofparticipantsintheSwedishObeseSubjectsStudy
after an average of 11 years found that bariatric surgery was
associated with a 29% reduction in all-cause mortality after
accounting for sex, age and risk factors in this severely obese
group [5]. Bariatric surgery also led to a speciﬁc reduction in
cancer incidence in women [46]. Other studies have conﬁrmed
this mortality advantage when compared with community
matched control subjects [9,47]. A large retrospective cohort
studyofalmost8000patientswhohadundergonegastricbypass
surgery were compared for long-term mortality with age-, sex-
and BMI-matched control subjects who had applied for driver’s
licences (Utah, USA) [9].The analysis reported an adjusted long-
term all-cause mortality reduction of 40% in the surgical group.
Speciﬁcmortalityreductionsintheoperatedgroupwere56%for
coronary artery disease, 92% for diabetes and 60% for cancer
when compared with matched controls.
It would be expected that morbidly obese patients who have
bariatric surgery as a treatment primarily for Type 2 diabetes
wouldalsoexperiencethebeneﬁtsofweightlossonotheraspects
of their health; for example, debilitating osteoarthritis or
obstructive sleep apnoea. Many studies have demonstrated
major improvements in health-related quality of life following
bariatric surgery using both generic and obesity-speciﬁc quality-
of-life instruments [48,49].
Is bariatric surgery cost-effective?
The costs of Type 2 diabetes are substantial. In the USA, the
lifetime cost has been estimated at $US172 000 for a person
diagnosedattheageof50 yearsand$US305 000ifdiagnosedat
the age of 30 years [50]. The estimate included both the direct
medical costs of diabetes and its complications and indirect
costs caused by work absence, reduced productivity at work,
disability and premature death. Over 60% of the medical cost
was incurred within 10 years of diagnosis. Bariatric surgery for
severe obesity, regardless of diabetes status, has been assessed as
cost-effective[51]and,insomeanalyses,costsavingordominant
[52].
A literature review identiﬁed three cost-effective analyses
of bariatric surgery for patients speciﬁcally with diabetes
(Table 4). All three studies found bariatric surgery to be either
very cost-effective or dominant as a therapy for Type 2 diabe-
tes relative to standard therapy. Study analyses have been
conservative. The ﬁnding of ‘cost-effectiveness’ indicates that
health beneﬁts are achieved at an acceptable price relative to
country-speciﬁc cost-effectiveness thresholds. The ‘dominant’
result indicates that an intervention generates both cost savings
and health beneﬁts over the lifetime of the cohort. This is a rare
Table 2 Two-and10-yeardiabetesincidenceandremission*ratesfromthe
Swedish Obese Subjects Study [7]
Surgical Control
2-year incident 1% 8%
10-year incident 8% 24%
2-year remission 72% 21%
10-yearremission 36% 13%
*Remission based on fasting plasma glucose < 7.0 mmol⁄l and
not on hypoglycaemic therapy [7].
Table 3 Mortality hazard ratios for white non-smokers [44]
22.5–25
kg⁄m
2
30–35
kg⁄m
2
35–40
kg⁄m
2
40–45
kg⁄m
2
White women 1.0 1.44 1.88 2.51
White men 1.0 1.44 2.06 2.93
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based on economic criteria.
It is recognized that cost-effectiveness studies have not been
conducted in low- and middle-income countries where high-
cost interventions for macro- and microvascular complications
may not be available. However, life expectancy might indeed be
improved by bariatric surgery in these settings and morbidity
decreased. It is up to each health system to determine whether
bariatric surgery with its support services is economically
appropriate when weighed against the provision of essential
medicines and other secondary prevention initiatives, such as
foot care, education and retinal screening, which can be cost
saving in low-income countries.
What eligibility guidelines exist?
A number of guidelines exist on the use of bariatric surgery for
the treatment of severe obesity in general, and for the treatment
of Type 2 diabetes in particular. They are summarized in
Table 5. Most of the existing guidelines reﬂect the expert
recommendations of the National Institutes of Health (NIH)
Consensus Development Conference Statement March 1991.
The current NIH website warns that their information is dated
and provided solely for historic purposes [53].
A recent Diabetes Surgery Summit of 50 international experts
examinedgastrointestinalsurgeryforthemanagementofType 2
diabetes. Delegates strongly endorsed that conventional
gastrointestinal surgery—Roux-en-Y gastric bypass (RYGB),
laparoscopic adjustable gastric band (LAGB) or bilio-pancreatic
diversion (BPD)—should be considered for the treatment of
Type 2 diabetes in acceptable surgical candidates with BMI
>3 5k g⁄m
2 who are inadequately controlled by lifestyle and
medicaltherapy.Furthertrialevidencewasdeemednecessaryfor
inadequately controlled Type 2 diabetes in candidates suitable
for surgery with mild-to-moderate obesity (BMI 30–35 kg⁄m
2)
[14].
Recommendations for adolescents
Long-term whole-of-family lifestyle change, with high-quality
medical management, is the mainstay of paediatric obesity
treatment. However, the growing prevalence of severe obesity in
children and adolescents demonstrates a need for additional
therapy. Bariatric surgery is only considered suitable for
adolescents of developmental and physical maturity. There are
a range of guidelines and consensus reports that have similar
recommendations.
A recent position statement was developed by the Australian
and New Zealand Colleges for paediatric physicians and
surgeons and the Obesity Surgery Society of Australia and New
Zealand [54]. The statement recommended surgery be
considered if adolescents had BMI > 40 kg⁄m
2,o r>3 5k g⁄m
2
with severe co-morbidities (including Type 2 diabetes), were
aged 15 years or more, with Tanner pubertal stage 4 or 5 and
skeletal maturity,and could provide informed consent.Potential
candidates should have failed a multidisciplinary programme of
lifestyle  pharmacotherapy for 6 months, and they and their
Table 4 Cost-effectiveness of bariatric procedures in people with diabetes
Study Type 2 diabetes status Total costs QALYs
Incremental
cost-effectiveness
ratio (ICER),
Cost per QALY
Cost-effectiveness
threshold⁄interpretation
Keating et al. [76], Australia,
$A 2006, lifetime
$A50 000
Standard care* Recently diagnosed 101 376 14.5 — —
Banding surgery Recently diagnosed 98 931 15.7 (ICER N⁄A)
Save $2444
Generate 1.2 QALYs
Dominant
Hoerger et al. [77], USA,
$US 2005, lifetime
$US50 000
Standard care* Recently diagnosed 71 130 9.55 — —
Bypass surgery Recently diagnosed 86 655 11.76 7000 Very CE
Banding surgery Recently diagnosed 89 029 11.12 11 000 Very CE
Standard care* Established 79 618 7.68
Bypass surgery Established 99 944 9.38 12 000 Very CE
Banding surgery Established 96 921 9.02 13 000 Very CE
Picot et al. [51], UK,
£ 2006, 20 years
£20–30 000
Standard care* Recently diagnosed 31 683 10.39 — —
Banding surgery Established 33 182 11.49 1367 Very CE
*Base case.
CE, cost-effective; QALY, quality-adjusted life-years.
In mid 2006: 1 Euro = $A1.72⁄£0.69⁄$US1.28.
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in post-surgical therapy and follow-up. Surgery should be
provided in units afﬁliated with teams experienced in the
assessment and long-term follow-up of the metabolic and
psychosocial needs of adolescent patients. Very similar
eligibility criteria, with some variation in youngest age and
BMI, have been listed in European and US publications [10,55].
This IDF position statement advises that only two procedures,
namely Roux-en-Y gastric bypass (RYGB) and laparoscopic
adjustable gastric banding (LAGB), are currently conventional
bariatric surgical procedures for adolescents.
Do procedures vary in effectiveness?
A number of bariatric surgical procedures are effective in
achieving weight loss. Those that involve more extensive
surgery, such as Roux-en-Y gastric bypass, generally lead to
greater weight loss and more profound metabolic changes, at
least initially, than less invasive, non-diversionary procedures
such as laparoscopic adjustable gastric banding. Roux-en-Y
gastric bypass procedures inﬂuence the gut hormonal milieu and
provide an early non-weight related improvement in glycaemic
control of Type 2 diabetes. It is not clear if these changes are
durable or have a fundamental effect on the underlying
mechanisms driving Type 2 diabetes. In the longer term,
weight loss may be the key beneﬁt. There is absolutely no
evidence to support subcutaneous lipectomy (liposuction) as a
treatment for Type 2 diabetes in obese patients [56].
A systematic review of the literature by Buchwald et al.[ 6 ]
reported that diabetes remits or improves in the majority of
patients after bariatric surgery. The procedures producing
greater excess weight loss lead to higher remission rates
(Table 6). This review, however, was limited by the quality of
the available literature where follow-up varied, there was no
consistent deﬁnition of remission, and biochemical measures of
remission were usually not reported.
The choice of bariatric procedure is complex, requiring a
careful risk–beneﬁt analysis and acceptance of variation in
regional practice and expertise. The decision must be made by
severely obese patients in consultation with their bariatric
surgical multidisciplinary team.
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Table 6 Estimated weight loss and percentage of those with diabetes who
remit at 2 years after conventional bariatric procedures*
% excess
BMI loss
% remission
of diabetes
Bilio-pancreatic diversion 73 95
Roux-en-Y gastric bypass 63 80
Laparoscopic adjustable
gastric band
49 57
*Systematic review (Buchwald et al. [6]).
Mean % on BMI in excess of 25% that is lost.
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patients with Type 2 diabetes include:
• Expertise and experience in the bariatric surgical procedures
• The patient’s preference when the range of risks and beneﬁts,
the importance of compliance, and the effects on eating
choices and behaviours have been fully described
• The patient’s general health and risk factors associated with
high perioperative morbidity and mortality
• The simplicity and reversibility of a procedure
• The duration of Type 2 diabetes and the degree of apparent
residual B-cell function
• The follow-up regimen for the procedure and the commitment
of the patient to adhere to it
It is important to recognize that all conventional surgical
procedures vary in their risks and beneﬁts and, to date, there are
few hard data that can be used to match patients to procedures.
Recommendations made by this consensus apply to currently
accepted bariatric surgical procedures and do not apply to new
experimental procedures or devices.
The consensus group consider that Roux-en-Y gastric bypass,
laparoscopic adjustable gastric banding, bilio-pancreatic
diversion (BPD) and the duodenal switch variant (BPD-SD),
and sleeve gastrectomy (SG) as currently accepted procedures
[57]. However, it was acknowledged that there was limited
medium- or long-term data regarding sleeve gastrectomy, and
there are safety, nutritional and metabolic concerns with
bilio-pancreatic diversion and the duodenal switch variant.
Two procedures were considered accepted procedures in ado-
lescents—Roux-en-Y gastric bypass and laparoscopic adjustable
gastric banding (see Recommendations for adolescents above).
What are the risks of bariatric surgery?
The 30-day mortality associated with bariatric surgery is
estimated at 0.1–0.3%, a rate similar to that for laparoscopic
cholecystectomy [58] and described as ‘low’ [59]. Programme
andpatientfactorsfoundtobeassociatedwithincreasedriskare
showninTable 7. The presence of Type 2 diabetes has not been
found to be associated with increased risk for bariatric surgery.
The most common complications of bariatric surgery include
anastomotic and staple-line leaks (3.1%), wound infections
(2.3%), pulmonary events (2.2%) and haemorrhage (1.7%).
Morbidity rates are lower after laparoscopic procedures, which
constituteasteadilyincreasingproportionofbariatricoperations
[60].
A new study by the US Agency for Healthcare Research and
Quality reported a 21% decline in complications after bariatric
surgery between 2002 and 2006 [61]. This work compared
complications among > 9500 patients who underwent obesity
surgery at 652 hospitals in 2001–2002 vs. 2005–2006.
Complication rates fell from 24 to 15%, despite increases in
the percentage of older and sicker operative patients. Post-
surgical infection rates dropped by 58%, while other
complications such as abdominal hernias, staple leakage,
respiratory failure and pneumonia diminished by 29–50%.
Other complications remained unchanged (ulcers, dumping,
haemorrhage, wound re-opening, deep-venous thrombosis and
pulmonary embolism, heart attacks and strokes) and none
increased.
Earlypost-operativemorbidityandmortalityarerelatedtothe
complexity of the surgery. The US Bariatric Outcomes
Longitudinal Database (BOLD) reviewed over 57 000
consecutive procedures and reported one or more complication
at 1-year rates of 4.6, 10.8, 14.9 and 25.7% following
laparoscopic adjustable gastric band, sleeve gastrectomy,
Roux-en-Y gastric bypass and bilio-pancreatic diversion,
respectively [62]. Thirty-day post-surgical mortality follows a
similar trend, with 0.1% for laparoscopic adjustable gastric
band, 0.5% for Roux-en-Y gastric bypass and 1.1 for bilio-
pancreatic diversion [58]. The US Agency for Healthcare
Research and Quality reported a ninefold increase in bariatric
surgery for the period 1998–2004, with a reduction in overall
early mortality from 0.89 to 0.19%. Improvements have been
attributed to higher hospital volumes, a move to laparoscopic
surgery and an increase in banding procedures [61].
Longer-term surgical complications and need for surgical
revisions are not uncommon and expected problems are usually
speciﬁc to the surgical intervention.
Earlydetectionandappropriatemanagementofcomplications
is very important. All those managing post-bariatric surgical
patientsshouldhavealowthresholdforsurgicalreferralshoulda
complication be suspected. Longer-term concerns, especially
with Roux-en-Y gastric bypass and bilio-pancreatic diversion,
include vitamin and mineral deﬁciencies, osteoporosis and,
rarely, Wernicke’s encephalopathy and severe hypoglycaemia
from insulin hypersecretion [11,63]. Clinical guidelines
developed by the American Association of Clinical Endocri
nologists, The Obesity Society and the American Society for
Metabolic and Bariatric Surgery address these important issues
Table 7 Patient and programme factors associated with risk of surgery
Programme—surgical factors
‘higher risk’
Patients’ factors ‘higher risk’
[80,81]
Surgeon inexperience or in
learning curve for the
particular procedure
Older age
Low volume centre or
surgeon performing surgery
occasionally
Increasing BMI
Morbidity and mortality
increase with the complexity
of the procedure
Male gender
Open compared with
laparoscopic procedures
Hypertension
Revisional surgery Obstructive sleep apnoea
High risk of pulmonary
thromboembolism
Limited physical mobility
DIABETICMedicine Original article
ª 2011 The Authors.
Diabetic Medicine ª 2011 Diabetes UK 635[11].Asummaryofnutritionalriskwitheachprocedureisshown
in Table 8. This does not reﬂect all nutritional risks. Long-term
dietary advice, evaluation and supplementation are required for
all procedures.
Therisksofeachprocedureneedtobeconsideredinthelightof
potential reductions in mortality, morbidity or co-morbidity,
quality of life and productivity. Realistic expectations are
important and the risk–beneﬁt ratio assessed individually for
eachpatient,accountingforbothperi-operativeriskandpossible
long-term complications [59].
Continuing efforts are required to monitor the safety, efﬁcacy
and long-term effects of bariatric surgery. There is a range of
national bariatric surgery registries and continuing long-term
longitudinal studies. We encourage the expansion of national
registries and acknowledge that these must be well resourced to
function appropriately. Severe obesity and Type 2 diabetes are
chronic conditions needing a chronic-disease approach to care.
Components of successful bariatric surgery
There is a range of comprehensive guidelines for the use of
bariatric procedures for obesity, including the UK National
Institute for Health and Clinical Excellence (2006) [12], the
combined American Association of Clinical Endocrinologists,
TheObesitySocietyandtheAmericanSocietyforMetabolicand
Bariatric Surgery guidelines (2008) [11] and European clinical
guidelines (2007) [10].
Text box 4 Considerations with respect to Type 2 diabetes
and components of successful programmes include:
• Bariatric surgery is a component of the ongoing process of
chronic disease management of Type 2 diabetes and obesity
• Bariatric surgery should be performed in high-volume centres
with multidisciplinary teams that are experienced in the
management of obesity and diabetes. Members of the team
should have understanding across disciplines and work
together with common expectations and goals. The team
needs to integrate with primary care, diabetes management,
nutritional and lifestyle support, and surgeon’s teams with
consistent messages and agreed policies
• The surgical team must have undertaken relevant supervized
training and have specialist experience in types of bariatric
surgery performed within the programme
• Pre-surgical assessment needs to be comprehensive, including
assessment of metabolic, physical, psychological and nutri-
tional health. Patients should have realistic expectations of the
risks and beneﬁts of surgery along with their lifelong role in
lifestyle intervention, nutritional support and follow-up
• Management of diabetes and other co-morbidities should be
optimized and short-term pre-operative weight loss considered
to improve health and visibility at the time of surgery
• The multidisciplinary team need to understand and recognize
earlyandlong-termcomplicationsinatimelymannerandknow
when to refer back to the surgeon or others for speciﬁc care
• Lifelong follow-up on at least an annual basis is needed for
ongoing lifestyle support, and post-surgical and diabetes
monitoring
• Teams should collect prospective data and measure diabetes
outcomes in methods consistent with IDF recommendations
• Regular, post-operative nutritional monitoring is required,
with attention to appropriate diet, monitoring of micronutri-
ent status and individualized nutritional supplementation,
support and guidance to achieve long-term weight loss and
weight maintenance
• Follow-up should include a psychological evaluation, support
and therapy if appropriate. Mental illness, especially depres-
sion, is common in diabetes and severe obesity
• In order to help sustain weight loss from bariatric surgery,
patients must be committed to increased levels of ongoing
daily physical activity
• All practices are encouraged to engage and promote national
programmes of ‘centres of excellence’ or equivalent and collect
prospective data through registries
Diabetes—who to consider for surgery?
There is clear evidence that bariatric surgery is a very effective
therapy for obese patients with Type 2 diabetes. The place of
surgery in diabetes treatment algorithms needs to be established
(see below). Currently, surgery is considered optional and, as
such, in the countries with the highest bariatric surgery uptake,
less than 2% of eligible patients are treated annually.
Indications for bariatric surgery typically classify those who
areeligibleforsurgery,butarecommendationofsurgicalreferral
as best practice or prioritization has not been widely considered.
Diabetes management algorithms should now include points at
whichbariatricsurgeryshouldbeconsideredandpointsatwhich
referral is recommended or prioritized (Table 9).
Table 8 A summary of more common nutritional concerns for each
procedure
LAGB SG RYGB BPD BPD-DS
Iron + ++ +++ +++ ++
Thiamine + ++ + + +
Vitamin B12 + ++ +++ ++ ++
Folate ++ ++ ++ ++ ++
Calcium + ++ ++ +++ +++
Vitamin D + + ++ +++ +++
Protein + + + ++ ++
Fat-soluble
vitamins and
essential fatty acids
+ + + +++ +++
+, recommended daily intake (allowance) or standard multivi-
tamin preparation likely to be sufﬁcient.
++, signiﬁcant risk of deﬁciency or increased requirements.
Speciﬁc supplementation is appropriate especially in higher-risk
groups.
+++, high risk of deﬁciency. Additional speciﬁc supplementa-
tion is necessary to prevent deﬁciency. Careful monitoring is
recommended. Supplementation well in excess of daily
requirements may be necessary.
BPD, bilio-pancreatic diversion; BPD-DS, bilio-pancreatic
diversion with duodenal switch; LAGB, laparoscopic adjustable
gastric band; RYGB, Roux-en-Y gastric bypass; SG, sleeve
gastrectomy.
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surgery should consider BMI, ethnicity, associated weight-
related co-morbidity, weight trajectory and the response of
diabetes and co-morbidity to optimal medical therapy.
Conditional eligibility or prioritization should be assessed by a
teamspecializingindiabetes.Surgicalreferralimpliesathorough
bariatric surgical multidisciplinary team assessment of risk and
beneﬁt.
Contraindications for bariatric surgery include: current drug
or alcohol abuse; uncontrolled psychiatric illness; and lack of
comprehension of the risks–beneﬁts, expected outcomes,
alternatives and lifestyle changes required with bariatric
surgery [11]. In addition, there are general conditions that
would contraindicate elective surgery and speciﬁc conditions
that substantially increase the risk of surgery, later
complications or poor outcomes. These should be assessed
by the surgical team.
Integration into diabetes treatment algorithms
Existing international treatment guidelines for Type 2 diabetes
provide little information or direction on the role of bariatric
interventions in treatment. By contrast, the American Diabetes
Associationrecommendsthatbariatricsurgerybeconsideredasa
treatment option for Type 2 diabetes when the patient’s BMI
exceeds 35 kg⁄m
2 [63]. Algorithms developed for treating
Type 2 diabetes should include recommendations as to where
bariatric surgery is an option and the circumstances where it
should be prioritized.
Almost all severely obese patients are unsuccessful in their
efforts to achieve sustained and signiﬁcant weight loss and there
is evidence that weight loss induced by bariatric surgery can lead
to remission of hyperglycaemia in the majority of patients with
diabetes [6,64]. Earlier intervention increases the likelihood of
remission [65,66]. In the remaining patients, residual hyper-
glycaemia is easier to manage following bariatric surgery. It can
therefore be argued that bariatric surgery for the severely obese
with Type 2 diabetesshould be considered early asan option for
eligible patients, rather than being held back as a last resort.
Equity of access to bariatric surgery
Obesity is more common in socio-economically disadvantaged
people in the developed world, but the vast majority of bariatric
surgery procedures in the developed world are performed in the
private sector. Current access to surgical treatment for people
with severe obesity and Type 2 diabetes is not equitable and
discriminates against individuals who are most likely to beneﬁt.
Thereareparticularproblemsinthoseemergingcountrieswhere
rates of severe obesity are increasing rapidly and healthcare
resources are extremely limited.
There will be resource implications in the short term from
increasingaccesstobariatricsurgery,butitisessentialtoconsider
not just the ﬁnancial costs of the procedures and necessary
follow-up, but also the potential savings from achieving
improved control of Type 2 diabetes, its related metabolic and
other complications and co-morbidities.
Measuring diabetes-related outcomes
Thereneedstobeanagreeddeﬁnitionofsuccessand,onthebasis
of present data, the achievable goal of bariatric surgery is not
cure,butremission,ofthediabetesstate.Improvedpatienthealth
would be recognized by individualized optimization of the
metabolic state, which involves normalization or improvement
of the metabolic state (Text box 5).
Text box 5 Criteria for remission or optimal metabolic state
and substantial improvement
Optimization of the metabolic state may be deﬁned as:
• HbA1c £ 42 mmol⁄mol (6%)
• no hypoglycaemia
• total cholesterol < 4 mmol⁄l; LDL cholesterol < 2 mmol⁄l
• triglycerides < 2.2 mmol⁄l
• blood pressure < 135⁄85 mmHg
• > 15% weight loss
• with reduced medication from the pre-operated state or
without other medications (where medications are continued,
reduced doses from pre-surgery with minimal side effects
would be expected)
A substantial improvement in the metabolic state may be deﬁned as:
• lowering of HbA1c by > 20%
• LDL < 2.3 mmol⁄l
• blood pressure < 135⁄85 mmHg
with reduced medication from the pre-operated state
The above deﬁnitions, with a focus on diabetes, complement
broadersuccessmeasures,includingsubstantialsustainedweight
loss, improved quality of life and improvement or remission of
obesity-associated co-morbidity.
Table 9 Eligibility and prioritization for bariatric surgery based on failed
non-surgical weight-loss therapy*, BMI, ethnicity and disease control
BMI range Eligible for surgery Prioritized for surgery
<3 0k g⁄m
2 No No
30–35 kg⁄m
2 Yes—conditional No
35–40 kg⁄m
2 Yes Yes—conditional
>4 0k g⁄m
2 Yes Yes
*In all cases, patients should have failed to lose weight and
sustain signiﬁcant weight loss through non-surgical weight-
management programmes, and have Type 2 diabetes that has
not responded adequately to lifestyle measures ( metformin)
with a HbA1c < 53 mmol⁄mol (7%).
Action points should be lowered by 2.5 BMI point levels for
Asian people [74].
HbA1c > 58 mmol⁄mol (7.5%) despite fully optimized con-
ventional therapy, especially if weight is increasing, or other
weight responsive co-morbidities not achieving targets on
conventional therapies. For example, blood pressure, dyslip-
idaemia and obstructive sleep apnoea.
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Novel bariatric–metabolic procedures
Several novel procedures have developed from elegant
experiments using rodent models to examine the mechanism of
actionofbariatricsurgery.Theaimhasbeentoenhancethenon-
weight-loss glycaemic control beneﬁts of the gastrointestinal
interventions. These procedures may evolve as therapy for
Type 2 diabetes in those withoutsigniﬁcant weightissues. These
novel procedures include duodenal–jejunal bypass (DJB) [67]
and ileal interposition (IT) [68].
First described by Rubino [69], duodenal–jejunal bypass is a
stomach-sparing bypass of a short portion of proximal intestine,
comparable with the segmentexcluded in a standard Roux-en-Y
gastricbypass.Anumberofearlyhumanclinicaltrialshavebeen
performed and improvements in glycaemic control have been
reported,butthesemaybelessimpressiveinsubjectswithalower
BMI [70,71].
Ilealinterpositioninvolvesthesurgicaltranspositionofasmall
segment of ileum into the proximal intestine. Generally, short-
term studies in humans have reported improved glycaemia
[72,73].
These procedures remain experimental and are likely to
require technical reﬁnements before larger-scale longer-term
safety and efﬁcacy studies.
Novel bariatric–metabolic devices
Multiple, mostly novel, devices and techniques are being
explored to utilize the gatrointestinal tract’s putative
mechanism for altering energy balance and for non-weight-loss
effects on glucose tolerance. In general, the techniques can be
divided by mode of placement into those that are upper
gastrointestinal endoscopic or laparoscopic, with some
combining approaches.
Endoscopically placed upper gastrointestinal devices include
the simple positioning of a device in the upper gastrointestinal
tract. Examples include intra-gastric balloons, which are
currently available for temporary placement (usually 6 months,
but repeat treatment for extending the duration of treatment
beyond 2 years have been reported) and which provide10–15%
weight loss duringthe period of placement, plus a range of novel
devices under development, which are placed in the stomach
tomimicrestriction,orplacedinthetrans-pyloricareatodelayor
regulate gastric emptying. Some endoscopically placed devices
are physically ﬁxed to the upper gastrointestinal tract to mimic
proximal gastric restriction of the laparoscopic adjustable
gastric band, while some use endoluminal impervious sleeves to
bypass the gastro-duodenal upper jejunal area to mimic the
Roux-en-Y gastric bypass, or bypass the duodenum and
proximal jejunum to mimic the duodenal–jejunal bypass.
A range of laparoscopic procedures to place novel electronic
gastric or gastro-duodenal motility stimulators, and vagal nerve-
blocking devices are also under investigation. Results in humans
todatehavebeenmixed,withsomedevicesprovidinginadequate
weight loss and others promising results. These are considered
less invasive than most conventional bariatric surgical
procedures.
Whilstthereisexcitementinthenovelmedicaldevicearea,the
efﬁcacy, safety, durability and clinical utility of many of these
procedures in the management of obese people with Type 2
diabetes is still to be established.
Recommendations
Management of diabetes (A)
1. Bariatric surgery is an appropriate treatment for people with
Type 2 diabetes and obesity (BMI equal to or greater than
35 kg⁄m
2) not achieving recommended treatment targets
with medical therapies, especially where there are other
obesity-related co-morbidities. Under some circumstances
people with a BMI of 30–35 kg⁄m
2 should be eligible for
surgery
2. It is up to each health system to determine whether bariatric
surgery with its support services is economically appropriate
3. Surgery should be considered as complementary to medical
therapies to reduce microvascular and cardiovascular risk
4. Patients should be assessed and managed by experienced
multidisciplinary teams
5. Glycaemic control should be optimized peri-operatively and
should be closely monitored after surgery
6. Ongoing and long-term nutritional supplementation and
support must be provided to patients after surgery
7. Apart from conventional procedures now in use, new tech-
niques and devices should be explored in research settings
only. Conventional procedures should be standardized. Other
techniques, variations and novel devices can be introduced
when supported by an evidence base
Management of diabetes (B)
8. Procedure selection requires appropriate assessment of risk
vs.beneﬁtofeachoperationaspartoftheprocessforselecting
the surgical treatment options for an individual patient
9. New bariatric procedures require robust assessment for their
efﬁcacy, safety and durability, using similar principles to
those for assessing new drug therapies and having regards to
the beneﬁts and risks of established therapy
10. Regional surgical expertise, multidisciplinary team experi-
ence and documented quality outcomes are important
factors in the regional choice of bariatric procedures
11. There should be a minimal accepted data set for pre-surgery
and follow-up to allow audit of clinical programmes, for
example:
• HbA1c
• fasting glucose and insulin
• BMI
• waist circumference
• retinopathy status (recent eye examination)
• nephropathy (e.g. test for microalbuminuria within previous
year)
• liver functions tests
• lipid proﬁle
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• foot exam (recent)
• documentation of medications—(glycaemia, lipids and hyper-
tension)
• these should be used preoperatively
• fasting C-peptide where available
• auto-antibody status, e.g. anti-GAD where available
12. All longitudinal studies should include quality of life as one
of the outcomes
13. It should be recognized that a prolonged period of normal-
ization of glycaemic control has beneﬁt even if there is
eventual relapse
Research recommendations
1. Studies are needed to establish more robust criteria than BMI
for predicting beneﬁt from surgery and deﬁne which patients
beneﬁt most from which procedures
2. Studies are needed to establish the beneﬁt of surgery for
persons with diabetes and BMI < 35 kg⁄m
2
3. Studies are needed to establish whether bariatric procedures
prevent or slow the progressive loss of B-cell function
characteristic of Type 2 diabetes
4. Studies are required to document the course of complications
after surgery to obtain evidence that surgery stabilizes and
ideally improves microvascular complications
5. Studies are needed to establish the duration of the beneﬁt of
surgery
6. Studies are needed to establish the mechanisms of the success
of surgery and the mechanisms associated with recurrence
7. Studies are needed to establish the long-term complications of
surgery
8. New techniques should be assessed rigorously for efﬁcacy and
safety and, ideally, mechanisms, and demonstrate their
equivalence or superiority to classical surgical techniques,
moving to human studies after appropriate preclinical studies
9. Studies are needed to deﬁne the best regimens of diabetes
management post-bariatric surgery
10. It will be important to phenotype candidates for surgery to
deﬁne what will be the most appropriate bariatric procedure
for persons with diabetes in different age groups, different
duration of diabetes, etc.
11. Randomized controlled trials are needed to evaluate and
compare different bariatric procedures for the treatment of
diabetes between themselves, as well as emerging non-
surgical therapies
Conclusion
Clinically severe obesity is a complex and chronic medical
condition. Bariatric surgery is an effective and cost-effective
therapy for Type 2 diabetes and obesity with an acceptable
safety proﬁle. Surgery provides an appropriate treatment for
people with Type 2 diabetes and obesity not achieving
recommended treatment targets with medical therapies,
especially when there are other major co-morbidities. National
guidelines for bariatric surgery need to be developed and
implemented for people with Type 2 diabetes. Bariatric
surgery should be incorporated into Type 2 diabetes treatment
algorithms and the establishment of national bariatric surgical
registries recommended.
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